Evidence map›Paper›PMID 29500489›Full record

ArticleJournal of gastroenterology2018

Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

Norio Akuta, Joji Toyota, Yoshiyasu Karino, Fusao Ikeda, Akio Ido, Katsuaki Tanaka, Koichi Takaguchi, Atsushi Naganuma, Eiichi Tomita, Kazuaki Chayama and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 2 countries.

Norio AkutaToranomon Hospital, Tokyo, Japan. norioakuta@toranomon.gr.jp.
Joji ToyotaSapporo-Kosei General Hospital, Sapporo, Japan.
Yoshiyasu KarinoSapporo-Kosei General Hospital, Sapporo, Japan.
Fusao IkedaOkayama University, Okayama, Japan.
Akio IdoKagoshima University, Kagoshima, Japan.
Katsuaki TanakaYokohama City University Medical Center, Yokohama, Japan.
Koichi TakaguchiKagawa Prefectural Central Hospital, Takamatsu, Japan.
Atsushi NaganumaTakasaki General Medical Center, Takasaki, Japan.
Eiichi TomitaGifu Municipal Hospital, Gifu, Japan.
Kazuaki ChayamaHiroshima University, Hiroshima, Japan.
Shigetoshi FujiyamaKumamoto Shinto General Hospital, Kumamoto, Japan.
Yukiko InadaMiyazaki Medical Center Hospital, Miyazaki, Japan.
Hitoshi YoshijiNara Medical University, Kashihara, Japan.
Hideaki WatanabeBristol-Myers Squibb K.K., Tokyo, Japan.
Hiroki IshikawaBristol-Myers Squibb K.K., Tokyo, Japan.
Fiona McPheeBristol-Myers Squibb, Wallingford, CT, USA.
Stephanie NovielloBristol-Myers Squibb, Princeton, NJ, USA.
Hiromitsu KumadaToranomon Hospital, Tokyo, Japan.
Bristol-Myers Squibb (Japan) · JPBristol-Myers Squibb (United States) · USSapporo Kosei General Hospital · JPToranomon Hospital · JPGifu Municipal Hospital · JPHiroshima University · JPKagawa Prefectural Central Hospital · JPKagoshima University · JPNara Medical University · JPNational Hospital Organization Takasaki Medical Center · JPOkayama University · JPUniversity of Miyazaki Hospital · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the UNITY-3 study, 96% sustained virologic response (SVR12) rate was observed in Japanese patients with hepatitis C virus (HCV) genotype (GT)-1 infection treated for 12 weeks with fixed-dose daclatasvir, asunaprevir, and beclabuvir (DCV-TRIO). As HCV clearance may improve liver outcomes, we assessed hepatic fibrosis and alpha-fetoprotein (AFP), a hepatocellular carcinoma risk marker, pre- and post-treatment in UNITY-3.

methodsTreatment-naive or interferon-experienced UNITY-3 patients with HCV GT-1 who received twice-daily DCV-TRIO were assessed for fibrosis [FibroTest; FibroScan; fibrosis-4 index (FIB-4), aspartate-aminotransferase-to-platelet-ratio index] and AFP at baseline and Weeks 4 (FIB-4 only), 12 or 24 post-treatment.

resultsOf 217 patients, 99% had GT-1b infection, 46% were aged > 65 years, 21% had compensated cirrhosis, and 26% baseline HCV-RNA > 10

conclusionsDCV-TRIO administered for 12 weeks to Japanese patients with primarily GT-1b infection achieved a high SVR12 rate and resulted in improved measures of hepatic fibrosis and serum AFP that may reduce the risk of future liver disease progression and hepatocellular carcinoma, particularly in those with compensated cirrhosis.

Indexed as

AdultAgedAged, 80 and overalpha-FetoproteinsAntiviral AgentsBenzazepinesBiopsyCarbamatesCarcinoma, HepatocellularDrug Therapy, CombinationElasticity Imaging TechniquesFemaleFollow-Up StudiesGenotypeHepacivirusHepatitis C, Chronic8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamidealpha-FetoproteinsAntiviral AgentsasunaprevirBenzazepinesCarbamatesdaclatasvirImidazolesIndolesIsoquinolinesPyrrolidinesSulfonamidesValineAlpha-fetoproteinAsunaprevirBeclabuvirDaclatasvirFibrosis

Identifiers

PMID29500489
OpenAlexW2789815096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.